Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

• New chemistry reduces barriers to scaling single-cell studies across research settings
• Launch planned for March 2026, available across Evercode Whole Transcriptome product line

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing.

Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to design large studies while maintaining sample resolution. The upgraded chemistry increases gene detection per cell while requiring fewer sequencing reads, helping reduce overall sequencing costs.

A new magnetic bead-based workflow replaces centrifugation steps and increases cell recovery by up to 75%, allowing researchers to generate more data from limited or precious samples. The streamlined process reduces hands-on time and pipetting steps and is designed to support laboratory automation, making the system accessible to laboratories with varying levels of single-cell experience.

Additionally, Evercode v4 eliminates off-target reads, enabling higher gene detection per cell even at lower sequencing depths and lower costs than other solutions. With higher sensitivity, Evercode v4 delivers higher biological resolution for researchers studying rare cell types or lowly expressed genes.

Evercode Whole Transcriptome v4 chemistry is available across the Evercode Whole Transcriptome product line, including Evercode Fixation and experiments processed through Parse’s GigaLab.

“Our goal from the beginning was to provide the research community with single cell technology that is scalable, accessible, and high-performing,” said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. “Evercode v4 reflects years of work and direct feedback from customers, delivering a leap forward in cell recovery and sensitivity combined with a simpler workflow.”

Evercode Whole Transcriptome v4 is planned to begin shipping in March 2026.

To learn more about the new chemistry, visit Parse at the upcoming AGBT meeting (Duval Room) or register for Parse’s upcoming webinar on Tuesday, March 3, 2026 at 9:00 AM Pacific:

https://resources.parsebiosciences.com/evercode-wt-v4.

About Parse Biosciences

Parse Biosciences, a QIAGEN Company, is a global life sciences leader whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development and the immune system. For more information, visit www.parsebiosciences.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN’s products, development timelines, marketing and/or regulatory approvals, financial and operational outlook, growth strategies, capital allocation strategies, collaborations and operating results (such as expected net sales and adjusted diluted earnings), the CEO transition plan, the acquisition of Parse Biosciences, including the timing and expected benefits thereof, and the synthetic share repurchase, including the timing and expected benefits thereof, are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to: challenges in managing a successful CEO transition and successor search while providing operational continuity and continued advancement of company strategy; challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistical dependencies); variability in operating results and the commercial development of products for customers in the Life Sciences and clinical healthcare markets; changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancement; developments or changes in the securities markets and fluctuations in the trading volume and market price of QIAGEN’s shares and the successful implementation of the synthetic share repurchase; QIAGEN’s ability to successfully close, integrate and achieve the expected benefits of its acquisition of Parse Biosciences, including fluctuating demand for QIAGEN’s products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional risks and uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other “force majeure” events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a more complete discussion of risks and uncertainties, please refer to the “Risk Factors” section in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Life Sciences